The different effects of psyllium husk and orlistat on weight control, the amelioration of hypercholesterolemia and non-alcohol fatty liver disease in obese mice induced by a high-fat diet

Deng, Zhitong; Meng, Cong; Huang, Haodong; Song, Siyu; Fu, Lin-Chun; Fu, Zhuotao

doi:10.1039/d2fo01161a

Cited by 15 publications

(14 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7(a,b)), which is a marker of gut homeostasis disorders. 38 As expected, compared with the HFD group, LP-HF02 treatment remarkably enhanced the ratio of Bacteroidetes/Firmicutes (Fig. 7(a,b)).…”

Section: Effect Of Lp-hf02 On Intestinal Microbiota In Obese Micesupporting

confidence: 80%

See 1 more Smart Citation

Lactobacillus plantarumHF02 alleviates lipid accumulation and intestinal microbiota dysbiosis in high‐fat diet‐induced obese mice

Chen

Zhao

et al. 2023

J Sci Food Agric

View full text Add to dashboard Cite

BACKGROUND Obesity is closely associated with lipid accumulation and intestinal microbiota dysbiosis. It has been proved that probiotics supplement contributes to alleviate obesity. The objective of this study was to investigate the mechanism by which Lactobacillus plantarum HF02 (LP‐HF02) alleviated lipid accumulation and intestinal microbiota dysbiosis in high‐fat diet‐induced obese mice. RESULTS Our results showed that LP‐HF02 ameliorated body weight, dyslipidemia, liver lipid accumulation, and liver injury in obese mice. As expected, LP‐HF02 inhibited pancreatic lipase activity in small intestinal contents and increased fecal triglyceride levels, thereby reducing dietary fat hydrolysis and absorption. Moreover, LP‐HF02 ameliorated the intestinal microbiota composition, as evidenced by the enhanced ratio of Bacteroides to Firmicutes, the decreased abundance of pathogenic bacteria (including Bacteroides, Alistipes, Blautia, and Colidextribacter) and the increased abundance of beneficial bacteria (including Muribaculaceae, Akkermansia, Faecalibaculum, and Rikenellaceae_RC9_gut_group). LP‐HF02 also increased fecal short‐chain fatty acids (SCFAs) levels and colonic mucosal thickness, and subsequently decreased serum lipopolysaccharide (LPS), interleukin‐1β (IL‐1β), and tumor necrosis factor‐α (TNF‐α) levels in obese mice. Additionally, reverse transcription quantitative polymerase chain reaction (RT‐qPCR) and Western blot results demonstrated that LP‐HF02 ameliorated hepatic lipid accumulation via activating the adenosine monophosphate (AMP)‐activated protein kinase (AMPK) pathway. CONCLUSION Therefore, our results indicated that LP‐HF02 could be considered as a probiotic preparation for preventing obesity. © 2023 Society of Chemical Industry.

show abstract

Section: Effect Of Lp-hf02 On Intestinal Microbiota In Obese Micesupporting

confidence: 80%

“…7(a)). Among them, Bacteroidetes and Firmicutes play vital roles in the regulation of energy metabolism in the host 38 . It has been indicated that intestinal microbiota characterized by an increase ratio of Firmicute/Bacteroidetes could more efficiently obtain energy from food 26 .…”

Section: Resultsmentioning

confidence: 99%

Lactobacillus plantarumHF02 alleviates lipid accumulation and intestinal microbiota dysbiosis in high‐fat diet‐induced obese mice

Chen

Zhao

et al. 2023

J Sci Food Agric

View full text Add to dashboard Cite

show abstract

“…The body weight of mice was recorded weekly. The final body length was measured for the calculation of Lee’s index as [body weight (g) 1/3 × 1000/body length (cm)]. − After 18 weeks, all mice were euthanized after 12 h of fasting. Subsequently, serum was obtained following centrifugation at 3500 rpm and 4 °C for 15 min.…”

Section: Methodsmentioning

confidence: 99%

Insoluble Dietary Fiber from Okara Combined with Intermittent Fasting Treatment Synergistically Confers Antiobesity Effects by Regulating Gut Microbiota and Its Metabolites

Wang,

Zhang

et al. 2023

J. Agric. Food Chem.

View full text Add to dashboard Cite

Insoluble dietary fiber (IDF) was recently revealed to have an antiobesity impact. However, the impact and potential mechanism of high-purity IDF derived from okara (HPSIDF) on obesity caused by a high-fat diet (HFD) remain unclear. Except for dietary supplementation, intermittent fasting (IF) has attracted extensive interest as a new dietary strategy against obesity. Thus, we hypothesize that HPSIDF combined with IF treatment may be more effective in preventing obesity. In this study, HPSIDF combined with IF treatment synergistically alleviated HFD-induced dyslipidemia, impaired glucose homeostasis, systemic inflammation, and fat accumulation. Furthermore, gut microbiota dysbiosis and lowered short-chain fatty acid synthesis were recovered by HPSIDF combined with IF treatment. Meanwhile, metabolomic analysis of feces revealed that HPSIDF combined with IF treatment obviously reversed the alterations of metabolic pathways and differential metabolites induced by HFD, which were linked to the modulations of the gut microbiota. Collectively, our findings indicated that HPSIDF combined with IF treatment has great potential to substantially enhance antiobesity efficacy by modulating the gut microbiota and its metabolites.

show abstract

“…Additionally, psyllium significantly increase concentrations of butyrogenic species including Roseburia , Lachnospira and Faecalibacterium concentrations and associated SCFAs, while also improving immune function [ 156 ]. Interestingly, recent findings suggest that psyllium husk is more effective than orlistat, a lipase inhibitor, in reducing liver cholesterol and TG levels in HFD-induced obesity [ 157 ]. Both psyllium husk and orlistat had beneficial effects on FXR receptor and sterol-27-hydroxylase expression, while regulating levels of important bile acids in the feces.…”

Section: Targeted Microbiota Therapiesmentioning

confidence: 99%

Treatment of Dyslipidemia through Targeted Therapy of Gut Microbiota

et al. 2023

View full text Add to dashboard Cite

Dyslipidemia is a multifaceted condition with various genetic and environmental factors contributing to its pathogenesis. Further, this condition represents an important risk factor for its related sequalae including cardiovascular diseases (CVD) such as coronary artery disease (CAD) and stroke. Emerging evidence has shown that gut microbiota and their metabolites can worsen or protect against the development of dyslipidemia. Although there are currently numerous treatment modalities available including lifestyle modification and pharmacologic interventions, there has been promising research on dyslipidemia that involves the benefits of modulating gut microbiota in treating alterations in lipid metabolism. In this review, we examine the relationship between gut microbiota and dyslipidemia, the impact of gut microbiota metabolites on the development of dyslipidemia, and the current research on dietary interventions, prebiotics, probiotics, synbiotics and microbiota transplant as therapeutic modalities in prevention of cardiovascular disease. Overall, understanding the mechanisms by which gut microbiota and their metabolites affect dyslipidemia progression will help develop more precise therapeutic targets to optimize lipid metabolism.

show abstract

The different effects of psyllium husk and orlistat on weight control, the amelioration of hypercholesterolemia and non-alcohol fatty liver disease in obese mice induced by a high-fat diet

Abstract: Obesity is a widespread medical problem, for which many drugs have been developed, each with its own limitations. Orlistat, a lipase inhibitor, functions as a fat absorption blocker and is...

Cited by 15 publications

References 77 publications

Lactobacillus plantarumHF02 alleviates lipid accumulation and intestinal microbiota dysbiosis in high‐fat diet‐induced obese mice

Lactobacillus plantarumHF02 alleviates lipid accumulation and intestinal microbiota dysbiosis in high‐fat diet‐induced obese mice

Insoluble Dietary Fiber from Okara Combined with Intermittent Fasting Treatment Synergistically Confers Antiobesity Effects by Regulating Gut Microbiota and Its Metabolites

Treatment of Dyslipidemia through Targeted Therapy of Gut Microbiota

Contact Info

Product

Resources

About